Compumedics Delivers Record Orders and Profit Surge in First Half FY26

Compumedics Limited ( (AU:CMP) ) has shared an announcement.

Compumedics reported a strong first half for FY26, with revenue from continuing operations rising 32% to A$31.0 million and profit before interest and tax jumping 664% to A$1.9 million. Net profit after tax attributable to members increased 124% to A$0.3 million, although the company chose not to declare an interim dividend.

The result was underpinned by record sales orders of A$34.9 million, up 6% on the prior corresponding period, driven by broad-based demand and better sales conversion in its core sleep and neuro platforms after a targeted refocus of the U.S. business. The half also included a A$4.9 million magnetoencephalography (MEG) order, and a 64% rise in SaaS and annuity sales, signalling a shift toward higher-quality recurring revenue and a more resilient earnings mix for stakeholders.

The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.35 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.

More about Compumedics Limited

Compumedics Limited is an Australian medical technology company focused on sleep and neuro diagnostics. It develops and sells systems and platforms used in sleep studies and neurological monitoring, with a growing emphasis on software-as-a-service and recurring annuity-style revenue, particularly in markets such as the U.S. where it has recently refocused its operations.

Average Trading Volume: 79,706

Technical Sentiment Signal: Buy

Current Market Cap: A$69.92M

Find detailed analytics on CMP stock on TipRanks’ Stock Analysis page.